Human Pulmonary Artery Smooth Muscle Cells Search Results


99
ATCC dmem medium
Dmem Medium, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/Primary+Pulmonary+Artery+Smooth+Muscle+Cells%3B+Normal%2C+Human/pm41997928-246-22-18
Average 99 stars, based on 1 article reviews
dmem medium - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

94
PromoCell smooth muscle cells
Smooth Muscle Cells, supplied by PromoCell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/Human+Pulmonary+Artery+Smooth+Muscle+Cells/pmc05408956-49-13-17
Average 94 stars, based on 1 article reviews
smooth muscle cells - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
ATCC human pulmonary artery smooth muscle cells hpasmc
TLR2 is a direct target gene of miR-143. (A) Computational analysis of the regulatory relationship between miR-143 and TLR2 mRNA. (B) Luciferase assay <t>of</t> <t>THP-1</t> cells co-transfected with wild-type or mutant TLR2 mRNA, and miR-143 or miRNA controls. (C) Luciferase assay of <t>HPASMC</t> cells co-transfected with wild-type or mutant TLR2 mRNA, and miR-143 or miRNA controls. (D) Relative expression of miR-143 in THP-1 cells transfected with miR-143 mimics. (E) Relative expression of miR-143 in HPASMC cells transfected with miR-143 mimics. n=3. *P<0.05 vs. negative control group. TLR2, Toll-like receptor 2; miR-143, microRNA-143; miR-cont, microRNA-control; 3′-UTR, 3′-untranslated region; WT, wild-type; MUT, mutant; NC, negative control.
Human Pulmonary Artery Smooth Muscle Cells Hpasmc, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/Primary+Pulmonary+Artery%3B+Smooth+Muscle+Cells%3B+Normal%2C+Human/pmc07930929-73-5-14
Average 94 stars, based on 1 article reviews
human pulmonary artery smooth muscle cells hpasmc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
Cell Applications Inc additional control donors hpasmc
TLR2 is a direct target gene of miR-143. (A) Computational analysis of the regulatory relationship between miR-143 and TLR2 mRNA. (B) Luciferase assay <t>of</t> <t>THP-1</t> cells co-transfected with wild-type or mutant TLR2 mRNA, and miR-143 or miRNA controls. (C) Luciferase assay of <t>HPASMC</t> cells co-transfected with wild-type or mutant TLR2 mRNA, and miR-143 or miRNA controls. (D) Relative expression of miR-143 in THP-1 cells transfected with miR-143 mimics. (E) Relative expression of miR-143 in HPASMC cells transfected with miR-143 mimics. n=3. *P<0.05 vs. negative control group. TLR2, Toll-like receptor 2; miR-143, microRNA-143; miR-cont, microRNA-control; 3′-UTR, 3′-untranslated region; WT, wild-type; MUT, mutant; NC, negative control.
Additional Control Donors Hpasmc, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/Human+Pulmonary+Artery+Smooth+Muscle+Cells%3A+HPASMC/pmc08268698-195-1-8
Average 95 stars, based on 1 article reviews
additional control donors hpasmc - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

91
Innoprot Inc pulmonary artery smooth muscle cells hpasmcs
(a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in <t>HPASMCs</t> exposed to sera of IPF patients. (a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs).
Pulmonary Artery Smooth Muscle Cells Hpasmcs, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/Human+Pulmonary+Artery+Smooth+Muscle/pmc06215550-42-3-19
Average 91 stars, based on 1 article reviews
pulmonary artery smooth muscle cells hpasmcs - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

90
ScienCell primary human pulmonary artery smooth muscle cells (hpasmcs)
(a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in <t>HPASMCs</t> exposed to sera of IPF patients. (a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs).
Primary Human Pulmonary Artery Smooth Muscle Cells (Hpasmcs), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/human+pulmonary+artery+smooth+muscle+cells/pm35453623-40-0-11
Average 90 stars, based on 1 article reviews
primary human pulmonary artery smooth muscle cells (hpasmcs) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Cambrex human pulmonary artery smooth muscle (pasm) cells
(a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in <t>HPASMCs</t> exposed to sera of IPF patients. (a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs).
Human Pulmonary Artery Smooth Muscle (Pasm) Cells, supplied by Cambrex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/human+pulmonary+artery+smooth+muscle+cells/us08044057-525-0-7
Average 90 stars, based on 1 article reviews
human pulmonary artery smooth muscle (pasm) cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Kurabo industries human pulmonary arterial smooth muscle cells
(a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in <t>HPASMCs</t> exposed to sera of IPF patients. (a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs).
Human Pulmonary Arterial Smooth Muscle Cells, supplied by Kurabo industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/human+pulmonary+arterial+smooth+muscle+cells/pm35641514-257-0-6
Average 90 stars, based on 1 article reviews
human pulmonary arterial smooth muscle cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
TCS Cellworks human pulmonary artery smooth muscle cells (hpasmc)
(a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in <t>HPASMCs</t> exposed to sera of IPF patients. (a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs).
Human Pulmonary Artery Smooth Muscle Cells (Hpasmc), supplied by TCS Cellworks, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/primary+human+pulmonary+artery+smooth+muscle+cell+line/pmc02947314-40-0-18
Average 90 stars, based on 1 article reviews
human pulmonary artery smooth muscle cells (hpasmc) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ScienCell human pulmonary vascular smooth muscle cells catalog # 3110
(a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in <t>HPASMCs</t> exposed to sera of IPF patients. (a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs).
Human Pulmonary Vascular Smooth Muscle Cells Catalog # 3110, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/human+pulmonary+artery+smooth+muscle+cells+catalog+++3110/bio_rxiv__2025__06__28__662142-90-0-12
Average 90 stars, based on 1 article reviews
human pulmonary vascular smooth muscle cells catalog # 3110 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
iCell Bioscience Inc human pulmonary artery smooth muscle cells (hpasmcs)
a Identification of <t>hPASMCs</t> by immunofluorescence staining. Scale bar: 100 μm. b , c The mRNA and protein levels of USP15 in the hypoxia-treated hPASMCs. d The protein levels of t-YAP1 and t-TAZ in the hypoxia-treated hPASMCs. e The protein levels of n-YAP1 and n-TAZ in the hypoxia-treated hPASMCs. Data are represented as the mean ± SD, n = 4 in each group. Compared with values at 0 h, * P < 0.05, ** P < 0.01.
Human Pulmonary Artery Smooth Muscle Cells (Hpasmcs), supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/human+pulmonary+artery+smooth+muscle+cells++hpasmcs+/pmc09898287-104-0-10
Average 90 stars, based on 1 article reviews
human pulmonary artery smooth muscle cells (hpasmcs) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Cambrex human pulmonary artery smooth muscle cells cc-25841
a Identification of <t>hPASMCs</t> by immunofluorescence staining. Scale bar: 100 μm. b , c The mRNA and protein levels of USP15 in the hypoxia-treated hPASMCs. d The protein levels of t-YAP1 and t-TAZ in the hypoxia-treated hPASMCs. e The protein levels of n-YAP1 and n-TAZ in the hypoxia-treated hPASMCs. Data are represented as the mean ± SD, n = 4 in each group. Compared with values at 0 h, * P < 0.05, ** P < 0.01.
Human Pulmonary Artery Smooth Muscle Cells Cc 25841, supplied by Cambrex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Human+Pulmonary+Artery+Smooth+Muscle+Cells/human+pulmonary+artery+smooth+muscle+cells+cc+25841/10__1097_slash_mbc__0b013e32830b2891-41-0-8
Average 90 stars, based on 1 article reviews
human pulmonary artery smooth muscle cells cc-25841 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


TLR2 is a direct target gene of miR-143. (A) Computational analysis of the regulatory relationship between miR-143 and TLR2 mRNA. (B) Luciferase assay of THP-1 cells co-transfected with wild-type or mutant TLR2 mRNA, and miR-143 or miRNA controls. (C) Luciferase assay of HPASMC cells co-transfected with wild-type or mutant TLR2 mRNA, and miR-143 or miRNA controls. (D) Relative expression of miR-143 in THP-1 cells transfected with miR-143 mimics. (E) Relative expression of miR-143 in HPASMC cells transfected with miR-143 mimics. n=3. *P<0.05 vs. negative control group. TLR2, Toll-like receptor 2; miR-143, microRNA-143; miR-cont, microRNA-control; 3′-UTR, 3′-untranslated region; WT, wild-type; MUT, mutant; NC, negative control.

Journal: Molecular Medicine Reports

Article Title: Rs41291957 polymorphism in the promoter region of microRNA-143 serves as a prognostic biomarker for patients with intracranial hemorrhage

doi: 10.3892/mmr.2021.11928

Figure Lengend Snippet: TLR2 is a direct target gene of miR-143. (A) Computational analysis of the regulatory relationship between miR-143 and TLR2 mRNA. (B) Luciferase assay of THP-1 cells co-transfected with wild-type or mutant TLR2 mRNA, and miR-143 or miRNA controls. (C) Luciferase assay of HPASMC cells co-transfected with wild-type or mutant TLR2 mRNA, and miR-143 or miRNA controls. (D) Relative expression of miR-143 in THP-1 cells transfected with miR-143 mimics. (E) Relative expression of miR-143 in HPASMC cells transfected with miR-143 mimics. n=3. *P<0.05 vs. negative control group. TLR2, Toll-like receptor 2; miR-143, microRNA-143; miR-cont, microRNA-control; 3′-UTR, 3′-untranslated region; WT, wild-type; MUT, mutant; NC, negative control.

Article Snippet: THP-1 (human monocytic cells) and human pulmonary artery smooth muscle cells (HPASMC) obtained from American Type Culture Collection were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Luciferase, Transfection, Mutagenesis, Expressing, Negative Control, Control

IL-16 mRNA is not a target of miR-143. (A) Computational analysis of the regulatory relationship between miR-143 and IL-16 mRNA. (B) Luciferase assay of THP-1 cells co-transfected with wild-type or mutant IL-16 mRNA, and miR-143 or miRNA controls. (C) Luciferase assay of HPASMC cells co-transfected with wild-type or mutant IL-16 mRNA, and miR-143 or miRNA controls. IL-16, interleukin-16; miR-143, microRNA-143; 3′-UTR, 3′-untranslated region; WT, wild-type; MUT, mutant.

Journal: Molecular Medicine Reports

Article Title: Rs41291957 polymorphism in the promoter region of microRNA-143 serves as a prognostic biomarker for patients with intracranial hemorrhage

doi: 10.3892/mmr.2021.11928

Figure Lengend Snippet: IL-16 mRNA is not a target of miR-143. (A) Computational analysis of the regulatory relationship between miR-143 and IL-16 mRNA. (B) Luciferase assay of THP-1 cells co-transfected with wild-type or mutant IL-16 mRNA, and miR-143 or miRNA controls. (C) Luciferase assay of HPASMC cells co-transfected with wild-type or mutant IL-16 mRNA, and miR-143 or miRNA controls. IL-16, interleukin-16; miR-143, microRNA-143; 3′-UTR, 3′-untranslated region; WT, wild-type; MUT, mutant.

Article Snippet: THP-1 (human monocytic cells) and human pulmonary artery smooth muscle cells (HPASMC) obtained from American Type Culture Collection were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Luciferase, Transfection, Mutagenesis

(a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in HPASMCs exposed to sera of IPF patients. (a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs).

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients

doi: 10.1155/2018/2639081

Figure Lengend Snippet: (a-b) Real-time assessment of intracellular ROS production and collagen I synthesis in HPASMCs exposed to sera of IPF patients. (a) Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course (a randomly selected representative experiment is reported) and values at 2 hours (steady state) were used in the future comparisons. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). (b) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Variations of COL1 promoter activation were kinetically followed for 10 hours (a randomly selected representative experiment is reported) and values at 8 hours (steady state) were used in the future comparison. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs).

Article Snippet: In this study, pulmonary artery smooth muscle cells (HPASMCs) isolated from human pulmonary arteries of healthy donors were used (Innoprot, Spain).

Techniques: Cell Culture, Fluorescence, Transduction, Activation Assay

(a-b) Effects of IPF sera on HPASMC intracellular ROS levels. Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA, then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). (b) In selected experiments, cells were pretreated for 60 min with the NADPH oxidase inhibitor diphenyleneiodonium (DPI) before exposure to the sera. (a-b) Data represent the variations of intracellular ROS levels after 2 hours of sera stimulation. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). P value indicating that the significance is reported in the figure.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients

doi: 10.1155/2018/2639081

Figure Lengend Snippet: (a-b) Effects of IPF sera on HPASMC intracellular ROS levels. Before stimulation, subconfluent human pulmonary artery smooth muscle cells (HPASMCs) were loaded with 10 μ M of H 2 -DCFDA, then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). (b) In selected experiments, cells were pretreated for 60 min with the NADPH oxidase inhibitor diphenyleneiodonium (DPI) before exposure to the sera. (a-b) Data represent the variations of intracellular ROS levels after 2 hours of sera stimulation. Fluorescence data were normalized for protein content and expressed as relative fluorescence units (RFUs). P value indicating that the significance is reported in the figure.

Article Snippet: In this study, pulmonary artery smooth muscle cells (HPASMCs) isolated from human pulmonary arteries of healthy donors were used (Innoprot, Spain).

Techniques: Cell Culture, Fluorescence

(a-b) Effects of IPF sera on HPASMC collagen I production. (a) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Data represent the collagen I promoter activity after 8 hours of sera stimulation. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs). (b) Subconfluent HPASMCs were stimulated for 48 hrs with basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD) and processed for collagen I quantification as reported in . In selected experiments, cells were pretreated for 60 min with the NADPH oxidase inhibitor diphenyleneiodonium (DPI) before exposure to the sera. Data are expressed as ng/ml collagen protein. P value indicating that the significance is reported in the figure.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients

doi: 10.1155/2018/2639081

Figure Lengend Snippet: (a-b) Effects of IPF sera on HPASMC collagen I production. (a) Before stimulation, subconfluent HPASMCs were transduced with lentiviral particles obtained from the COL1A1-LV-tGFP and EF1 α -LV-FP602 lentivectors and then cultured in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). Data represent the collagen I promoter activity after 8 hours of sera stimulation. Data are normalized for transduction efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1 α -LV-FP602 relative fluorescence units (RFUs). (b) Subconfluent HPASMCs were stimulated for 48 hrs with basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD) and processed for collagen I quantification as reported in . In selected experiments, cells were pretreated for 60 min with the NADPH oxidase inhibitor diphenyleneiodonium (DPI) before exposure to the sera. Data are expressed as ng/ml collagen protein. P value indicating that the significance is reported in the figure.

Article Snippet: In this study, pulmonary artery smooth muscle cells (HPASMCs) isolated from human pulmonary arteries of healthy donors were used (Innoprot, Spain).

Techniques: Transduction, Cell Culture, Activity Assay, Fluorescence

(a-b) Effects of IPF sera on HPASMC proliferation. Subconfluent HPASMCs were cultured for 48 hours in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). In selected experiments, cells were pretreated for 60 min with the NADPH oxidase inhibitor diphenyleneiodonium (DPI) before exposure to the sera. Data are expressed as ng/ml collagen protein. (a-b) Data are expressed as relative light units/sec (RLU/s). P value indicating that the significance is reported in the figure.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients

doi: 10.1155/2018/2639081

Figure Lengend Snippet: (a-b) Effects of IPF sera on HPASMC proliferation. Subconfluent HPASMCs were cultured for 48 hours in basal medium containing 10% ( v / v ) of sera from idiopathic pulmonary fibrosis (IPF), sera from idiopathic pulmonary fibrosis patients treated for 24 weeks with Pirfenidone (IPF + D), and healthy donors (HD). In selected experiments, cells were pretreated for 60 min with the NADPH oxidase inhibitor diphenyleneiodonium (DPI) before exposure to the sera. Data are expressed as ng/ml collagen protein. (a-b) Data are expressed as relative light units/sec (RLU/s). P value indicating that the significance is reported in the figure.

Article Snippet: In this study, pulmonary artery smooth muscle cells (HPASMCs) isolated from human pulmonary arteries of healthy donors were used (Innoprot, Spain).

Techniques: Cell Culture

a Identification of hPASMCs by immunofluorescence staining. Scale bar: 100 μm. b , c The mRNA and protein levels of USP15 in the hypoxia-treated hPASMCs. d The protein levels of t-YAP1 and t-TAZ in the hypoxia-treated hPASMCs. e The protein levels of n-YAP1 and n-TAZ in the hypoxia-treated hPASMCs. Data are represented as the mean ± SD, n = 4 in each group. Compared with values at 0 h, * P < 0.05, ** P < 0.01.

Journal: Experimental & Molecular Medicine

Article Title: USP15 promotes pulmonary vascular remodeling in pulmonary hypertension in a YAP1/TAZ-dependent manner

doi: 10.1038/s12276-022-00920-y

Figure Lengend Snippet: a Identification of hPASMCs by immunofluorescence staining. Scale bar: 100 μm. b , c The mRNA and protein levels of USP15 in the hypoxia-treated hPASMCs. d The protein levels of t-YAP1 and t-TAZ in the hypoxia-treated hPASMCs. e The protein levels of n-YAP1 and n-TAZ in the hypoxia-treated hPASMCs. Data are represented as the mean ± SD, n = 4 in each group. Compared with values at 0 h, * P < 0.05, ** P < 0.01.

Article Snippet: Human pulmonary artery smooth muscle cells (hPASMCs) were purchased from iCell Bioscience, Inc., Shanghai. hPASMCs were cultured in specific medium (PriMed-iCell-004-LS, iCell Bioscience, China) at 37 °C in a humidified incubator with 5% CO 2 . hPASMCs at passages 2-7 were used for further study.

Techniques: Immunofluorescence, Staining

Adenovirus delivering shRNA against hUSP15 was used to downregulate USP15 expression in hPASMCs. After 48 h of infection, cells were cultured under hypoxia for another 24 h. The protein level ( a ) and mRNA level ( b ) of USP15 in the treated cells were measured by western blotting and real-time PCR, respectively. c The abundance of PCNA protein was detected by western blot analysis. d A CCK-8 assay was performed to determine cell viability after treatments. e , f The protein levels of t-YAP1, t-TAZ, n-YAP1, and n-TAZ in the treated cells were measured by western blotting. g , h Cell migration in each group was determined by wound healing assay. Scale bar: 200 μm. Data are represented as the mean ± SD, n = 4 in each group.

Journal: Experimental & Molecular Medicine

Article Title: USP15 promotes pulmonary vascular remodeling in pulmonary hypertension in a YAP1/TAZ-dependent manner

doi: 10.1038/s12276-022-00920-y

Figure Lengend Snippet: Adenovirus delivering shRNA against hUSP15 was used to downregulate USP15 expression in hPASMCs. After 48 h of infection, cells were cultured under hypoxia for another 24 h. The protein level ( a ) and mRNA level ( b ) of USP15 in the treated cells were measured by western blotting and real-time PCR, respectively. c The abundance of PCNA protein was detected by western blot analysis. d A CCK-8 assay was performed to determine cell viability after treatments. e , f The protein levels of t-YAP1, t-TAZ, n-YAP1, and n-TAZ in the treated cells were measured by western blotting. g , h Cell migration in each group was determined by wound healing assay. Scale bar: 200 μm. Data are represented as the mean ± SD, n = 4 in each group.

Article Snippet: Human pulmonary artery smooth muscle cells (hPASMCs) were purchased from iCell Bioscience, Inc., Shanghai. hPASMCs were cultured in specific medium (PriMed-iCell-004-LS, iCell Bioscience, China) at 37 °C in a humidified incubator with 5% CO 2 . hPASMCs at passages 2-7 were used for further study.

Techniques: shRNA, Expressing, Infection, Cell Culture, Western Blot, Real-time Polymerase Chain Reaction, CCK-8 Assay, Migration, Wound Healing Assay

Adenovirus delivering overexpressed hUSP15 was used to upregulate USP15 expression in hPASMCs under normoxia. Western blot analysis ( a ) and real-time PCR ( b ) were conducted to determine the infectivity of Ad-hUSP15-OV after 72 h of infection. Afterward, hPASMCs were coinfected with adenovirus delivering overexpressed hUSP15 and hYAP1-sh or hTAZ-sh. c The expression level of PCNA in hPASMCs was detected by immunoblot analysis after coinfection. d A CCK-8 assay was performed to detect the viability of hPASMCs after coinfection. e , f The expression levels of t-YAP1, t-TAZ, n-YAP1, and n-TAZ in hPASMCs were detected by western blotting after coinfection. g , h Cell migration in hPASMCs was determined by wound healing assays after coinfection. Scale bar: 200 μm. Data are represented as the mean ± SD, n = 4 in each group. Compared to the Vector+NCsh-2 group, # P < 0.05, ## P < 0.01; compared to the hUSP15-OV + NCsh-2 group, * P < 0.05, ** P < 0.01.

Journal: Experimental & Molecular Medicine

Article Title: USP15 promotes pulmonary vascular remodeling in pulmonary hypertension in a YAP1/TAZ-dependent manner

doi: 10.1038/s12276-022-00920-y

Figure Lengend Snippet: Adenovirus delivering overexpressed hUSP15 was used to upregulate USP15 expression in hPASMCs under normoxia. Western blot analysis ( a ) and real-time PCR ( b ) were conducted to determine the infectivity of Ad-hUSP15-OV after 72 h of infection. Afterward, hPASMCs were coinfected with adenovirus delivering overexpressed hUSP15 and hYAP1-sh or hTAZ-sh. c The expression level of PCNA in hPASMCs was detected by immunoblot analysis after coinfection. d A CCK-8 assay was performed to detect the viability of hPASMCs after coinfection. e , f The expression levels of t-YAP1, t-TAZ, n-YAP1, and n-TAZ in hPASMCs were detected by western blotting after coinfection. g , h Cell migration in hPASMCs was determined by wound healing assays after coinfection. Scale bar: 200 μm. Data are represented as the mean ± SD, n = 4 in each group. Compared to the Vector+NCsh-2 group, # P < 0.05, ## P < 0.01; compared to the hUSP15-OV + NCsh-2 group, * P < 0.05, ** P < 0.01.

Article Snippet: Human pulmonary artery smooth muscle cells (hPASMCs) were purchased from iCell Bioscience, Inc., Shanghai. hPASMCs were cultured in specific medium (PriMed-iCell-004-LS, iCell Bioscience, China) at 37 °C in a humidified incubator with 5% CO 2 . hPASMCs at passages 2-7 were used for further study.

Techniques: Expressing, Western Blot, Real-time Polymerase Chain Reaction, Infection, CCK-8 Assay, Migration, Plasmid Preparation

a Anti-USP15 immunoprecipitation was used to determine the interaction between USP15 and YAP1 or TAZ in the control and hypoxic hPASMCs. b Anti-YAP1 immunoprecipitation to determine the interaction between YAP1 and USP15 in the control or hypoxic hPASMCs. c Anti-TAZ immunoprecipitation to determine the interaction between TAZ and USP15 in the control or hypoxic hPASMCs. d hPASMCs were infected with Ad-hUSP15-sh or Ad-NCsh-2 for 48 h. After 3 h of starvation, cells were exposed to hypoxia for 24 h and treated with CHX (25 μg/ml) or MG132 (5 μM) for 0, 1, 4, or 8 h (at the last 8 h of hypoxic time). Cell samples were harvested for immunoblot analysis to detect YAP1 expression. The percentage of YAP1/actin is shown in the right panel. e hPASMCs infected with Ad-hUSP15-OV or Ad-Vector were treated with MG132 (5 μM) under normoxia for 8 h, and cells were harvested for immunoprecipitation using anti-YAP1 antibody. f Under normoxia, infected hPASMCs were subjected to a CHX pulse-chase assay. Cell samples were harvested for immunoblot analysis to detect YAP1 expression. The percentage of YAP1/Actin is shown in the right panel. g His-tagged USP15 and Myc-tagged YAP1 were cotransfected into HEK293T cells. At 48 h post-transfection, cell samples were harvested for immunoprecipitation using an anti-His antibody. h HEK293T cells were cotransfected with Myc-tagged YAP1 and His-tagged USP15/vector. At 48 h post-transfection, cells were treated with CHX (25 μg/ml) for 0, 1, 4, and 8 h. YAP1 expression in cell samples was determined by western blot analysis using an anti-Myc antibody. The percentage of YAP1/actin is shown in the right panel. i His-tagged USP15, HA-tagged Ubi and Myc-tagged YAP1 were cotransfected into HEK293T cells. At 48 h post-transfection, cells were treated with MG132 (5 μM) for 5 h. Cell samples were then harvested for immunoprecipitation using anti-Myc antibody. Data are represented as the mean ± SD, n = 4 in each group.

Journal: Experimental & Molecular Medicine

Article Title: USP15 promotes pulmonary vascular remodeling in pulmonary hypertension in a YAP1/TAZ-dependent manner

doi: 10.1038/s12276-022-00920-y

Figure Lengend Snippet: a Anti-USP15 immunoprecipitation was used to determine the interaction between USP15 and YAP1 or TAZ in the control and hypoxic hPASMCs. b Anti-YAP1 immunoprecipitation to determine the interaction between YAP1 and USP15 in the control or hypoxic hPASMCs. c Anti-TAZ immunoprecipitation to determine the interaction between TAZ and USP15 in the control or hypoxic hPASMCs. d hPASMCs were infected with Ad-hUSP15-sh or Ad-NCsh-2 for 48 h. After 3 h of starvation, cells were exposed to hypoxia for 24 h and treated with CHX (25 μg/ml) or MG132 (5 μM) for 0, 1, 4, or 8 h (at the last 8 h of hypoxic time). Cell samples were harvested for immunoblot analysis to detect YAP1 expression. The percentage of YAP1/actin is shown in the right panel. e hPASMCs infected with Ad-hUSP15-OV or Ad-Vector were treated with MG132 (5 μM) under normoxia for 8 h, and cells were harvested for immunoprecipitation using anti-YAP1 antibody. f Under normoxia, infected hPASMCs were subjected to a CHX pulse-chase assay. Cell samples were harvested for immunoblot analysis to detect YAP1 expression. The percentage of YAP1/Actin is shown in the right panel. g His-tagged USP15 and Myc-tagged YAP1 were cotransfected into HEK293T cells. At 48 h post-transfection, cell samples were harvested for immunoprecipitation using an anti-His antibody. h HEK293T cells were cotransfected with Myc-tagged YAP1 and His-tagged USP15/vector. At 48 h post-transfection, cells were treated with CHX (25 μg/ml) for 0, 1, 4, and 8 h. YAP1 expression in cell samples was determined by western blot analysis using an anti-Myc antibody. The percentage of YAP1/actin is shown in the right panel. i His-tagged USP15, HA-tagged Ubi and Myc-tagged YAP1 were cotransfected into HEK293T cells. At 48 h post-transfection, cells were treated with MG132 (5 μM) for 5 h. Cell samples were then harvested for immunoprecipitation using anti-Myc antibody. Data are represented as the mean ± SD, n = 4 in each group.

Article Snippet: Human pulmonary artery smooth muscle cells (hPASMCs) were purchased from iCell Bioscience, Inc., Shanghai. hPASMCs were cultured in specific medium (PriMed-iCell-004-LS, iCell Bioscience, China) at 37 °C in a humidified incubator with 5% CO 2 . hPASMCs at passages 2-7 were used for further study.

Techniques: Immunoprecipitation, Control, Infection, Western Blot, Expressing, Plasmid Preparation, Pulse Chase, Transfection